X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs LUPIN LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS LUPIN LTD IPCA LABS/
LUPIN LTD
 
P/E (TTM) x 27.7 16.6 166.8% View Chart
P/BV x 2.1 3.9 54.9% View Chart
Dividend Yield % 0.2 0.8 30.4%  

Financials

 IPCA LABS   LUPIN LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-17
LUPIN LTD
Mar-16
IPCA LABS/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs6432,127 30.2%   
Low Rs5031,294 38.9%   
Sales per share (Unadj.) Rs254.4304.1 83.7%  
Earnings per share (Unadj.) Rs16.150.4 31.9%  
Cash flow per share (Unadj.) Rs29.860.7 49.1%  
Dividends per share (Unadj.) Rs1.007.50 13.3%  
Dividend yield (eoy) %0.20.4 39.8%  
Book value per share (Unadj.) Rs194.6243.8 79.8%  
Shares outstanding (eoy) m126.20450.58 28.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.35.6 40.0%   
Avg P/E ratio x35.733.9 105.0%  
P/CF ratio (eoy) x19.228.2 68.3%  
Price / Book Value ratio x2.97.0 42.0%  
Dividend payout %6.214.9 41.8%   
Avg Mkt Cap Rs m72,300770,740 9.4%   
No. of employees `00013.316.4 81.4%   
Total wages/salary Rs m6,96021,077 33.0%   
Avg. sales/employee Rs Th2,413.58,379.6 28.8%   
Avg. wages/employee Rs Th523.21,289.0 40.6%   
Avg. net profit/employee Rs Th152.41,388.7 11.0%   
INCOME DATA
Net Sales Rs m32,106137,016 23.4%  
Other income Rs m2261,877 12.0%   
Total revenues Rs m32,332138,893 23.3%   
Gross profit Rs m4,44837,535 11.8%  
Depreciation Rs m1,7304,635 37.3%   
Interest Rs m241446 54.0%   
Profit before tax Rs m2,70334,330 7.9%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m67511,536 5.9%   
Profit after tax Rs m2,02822,707 8.9%  
Gross profit margin %13.927.4 50.6%  
Effective tax rate %25.033.6 74.3%   
Net profit margin %6.316.6 38.1%  
BALANCE SHEET DATA
Current assets Rs m17,34097,790 17.7%   
Current liabilities Rs m9,55953,872 17.7%   
Net working cap to sales %24.232.1 75.6%  
Current ratio x1.81.8 99.9%  
Inventory Days Days10085 118.4%  
Debtors Days Days57121 46.9%  
Net fixed assets Rs m20,77986,379 24.1%   
Share capital Rs m252901 28.0%   
"Free" reserves Rs m24,499105,735 23.2%   
Net worth Rs m24,553109,844 22.4%   
Long term debt Rs m3,51753,739 6.5%   
Total assets Rs m39,595224,378 17.6%  
Interest coverage x12.277.9 15.7%   
Debt to equity ratio x0.10.5 29.3%  
Sales to assets ratio x0.80.6 132.8%   
Return on assets %5.710.3 55.5%  
Return on equity %8.320.7 40.0%  
Return on capital %10.521.2 49.5%  
Exports to sales %48.649.1 99.1%   
Imports to sales %14.27.4 191.3%   
Exports (fob) Rs m15,61767,244 23.2%   
Imports (cif) Rs m4,57110,199 44.8%   
Fx inflow Rs m15,61771,405 21.9%   
Fx outflow Rs m5,82817,807 32.7%   
Net fx Rs m9,79053,598 18.3%   
CASH FLOW
From Operations Rs m2,764-3,690 -74.9%  
From Investments Rs m-1,432-69,434 2.1%  
From Financial Activity Rs m-1,59158,126 -2.7%  
Net Cashflow Rs m-259-14,998 1.7%  

Share Holding

Indian Promoters % 45.9 46.6 98.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.4 11.3 100.9%  
FIIs % 25.3 31.9 79.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.1 172.3%  
Shareholders   36,892 98,259 37.5%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 18, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - FRESENIUS KABI ONCO. COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS